Aug. 16 at 10:55 PM
$KPTI I’m a very long shareholder and have lost hundreds of thousands off of this stock. I remember 5 short years ago it was the equivalent of
$350/share! At one point almost
$700/share ten years ago.
As a former pharma sr. Executive we would never have allowed an R&D budget to total
$1B + over the last 5 years without a subsequent dramatic spike in revenue which Paulson knew wasn’t happening!
It’s easy to see that Reshma’s influence dominated the c-suite conversations about strategic direction.
A prudent CEO, when confronted with the reality that cash runway was already compromised through debt relief would have told her that we have enough cash for one shot on goal: EC or MF. Pick one, expand the clinical sites 4-fold to ensure rapid patient accession and monitor this daily as if our company’s survival depends on it.
No sense of urgency, no corporate vision and weak leadership has destroyed amazing science!!
Now they have no control over what happens next. It’s whether VC saves it!
